ArticleAnesthesiology2010
Noble gas xenon is a novel adenosine triphosphate-sensitive potassium channel opener.
Article in Anesthesiology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- The cellular mechanisms associated with the anesthetic and neuroprotective properties of xenon: a systematic review of the preclinical literature.Frontiers in neuroscience · 2023Pooled it
- Xenon as an adjuvant to therapeutic hypothermia in near-term and term newborns with hypoxic-ischaemic encephalopathy.The Cochrane database of systematic reviews · 2018Pooled it
- Xenon in the treatment of panic disorder: an open label study.Journal of translational medicine · 2017Trial
- Neuroprotective effects of noble gases following acquired brain injury: a narrative review.Frontiers in pharmacology · 2026Review
- Developments in the Study of Inert Gas Biological Effects and the Underlying Molecular Mechanisms.International journal of molecular sciences · 2025Review
- Xenon gas as a potential treatment for opioid use disorder, alcohol use disorder, and related disorders.Medical gas research · 2025Review
- Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy.Journal of clinical medicine · 2023Review
- Review
- Xenon's Sedative Effect Is Mediated by Interaction with the Cyclic Nucleotide-Binding Domain (CNBD) of HCN2 Channels Expressed by Thalamocortical Neurons of the Ventrobasal Nucleus in Mice.International journal of molecular sciences · 2023Article
- Discovery of the Xenon-Protein Interactome Using Large-Scale Measurements of Protein Folding and Stability.Journal of the American Chemical Society · 2022Article
- Noble gas and neuroprotection: From bench to bedside.Frontiers in pharmacology · 2022Review
- Effect of Xenon Treatment on Gene Expression in Brain Tissue after Traumatic Brain Injury in Rats.Brain sciences · 2021Article
- Xenon treatment after severe traumatic brain injury improves locomotor outcome, reduces acute neuronal loss and enhances early beneficial neuroinflammation: a randomized, blinded, controlled animal study.Critical care (London, England) · 2020Article
- Neuroprotective Properties of Xenon.Molecular neurobiology · 2020Review
- Noble gas neuroprotection: xenon and argon protect against hypoxic-ischaemic injury in rat hippocampus in vitro via distinct mechanisms.British journal of anaesthesia · 2019Article
- Recent advances in perinatal neuroprotection.F1000Research · 2019Review
- Xenon Protects against Blast-Induced Traumatic Brain Injury in an In Vitro Model.Journal of neurotrauma · 2018Article
- Delivery of xenon-containing echogenic liposomes inhibits early brain injury following subarachnoid hemorrhage.Scientific reports · 2018Article
- Article
- The noble gas xenon provides protection and trophic stimulation to midbrain dopamine neurons.Journal of neurochemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAdenosine triphosphate-sensitive potassium (KATP) channels in brain are involved in neuroprotective mechanisms. Pharmacologic activation of these channels is seen as beneficial, but clinical exploitation by using classic K channel openers is hampered by their inability to cross the blood-brain barrier. This is different with the inhalational anesthetic xenon, which recently has been suggested to activate KATP channels; it partitions freely into the brain.
methodsTo evaluate the type and mechanism of interaction of xenon with neuronal-type KATP channels, these channels, consisting of Kir6.2 pore-forming subunits and sulfonylurea receptor-1 regulatory subunits, were expressed in HEK293 cells and whole cell, and excised patch-clamp recordings were performed.
resultsXenon, in contrast to classic KATP channel openers, acted directly on the Kir6.2 subunit of the channel. It had no effect on the closely related, adenosine triphosphate (ATP)-regulated Kir1.1 channel and failed to activate an ATP-insensitive mutant version of Kir6.2. Furthermore, concentration-inhibition curves for ATP obtained from inside-out patches in the absence or presence of 80% xenon revealed that xenon reduced the sensitivity of the KATP channel to ATP. This was reflected in an approximately fourfold shift of the concentration causing half-maximal inhibition (IC50) from 26 +/- 4 to 96 +/- 6 microm.
conclusionsXenon represents a novel KATP channel opener that increases KATP currents independently of the sulfonylurea receptor-1 subunit by reducing ATP inhibition of the channel. Through this action and by its ability to readily partition across the blood-brain barrier, xenon has considerable potential in clinical settings of neuronal injury, including stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.